


R&D Pipeline



antibody



protein



small molecule

© New Molecular Entity

Updated since Dec. 31, 2019

Nephrology

As of Mar. 31, 2020

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	CN						[Kirin-Amgen]
KHK7580 Evocalcet Oral	Calcimimetic	Secondary Hyperparathyroidism	CN KR TW HK						[Mitsubishi Tanabe Pharma]
©RTA 402 Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	Diabetic Kidney Disease	JP						[Reata]
KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Preeclampsia	JP						[In-House]
KHK7791 Tenapanor Oral	NHE3 Inhibitor	Hyperphosphatemia Under Maintenance Dialysis	JP						[Ardelyx]

Oncology

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Mycosis Fungoides and Sézary Syndrome Adult T-cell Leukemia/ Lymphoma	AU US EU others						[In-House] POTELLIGENT®
©KHK2375 Entinostat Oral	HDAC Inhibitor	Breast Cancer	JP						[Syndax]
KRN125 Pegfilgrastim Injection	Long-Acting Granulocyte Colony Stimulating Factor Product	Mobilization of Hematopoietic stem cell into Peripheral blood	JP						[Kirin-Amgen]
		Automated Injection Device for Decreasing the Incidence of Febrile Neutropenia in Patients Receiving Cancer Chemotherapy	JP						
©KHK2455 Oral	IDO1 Inhibitor	Solid Tumor	US						[In-House] Combination with KW-0761
		Urothelial carcinoma	US						[In-House] Combination with avelumab
©ME-401 Oral	PI3Kδ Inhibitor	B-cell malignancies	JP						[MEI Pharma]

Immunology/Allergy

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Axial Spondyloarthritis (axSpA)	TW						[Kirin-Amgen] Concurrent submit of an application for Psoriatic
		Psoriasis	JP						
		Psoriasis	MY CN MO						[Kirin-Amgen]
		Systemic Sclerosis	JP						
		Palmoplantar Pustulosis	JP						
©KHK4083 Injection	Anti-OX40 Fully Human Antibody	Ulcerative Colitis	US EU others						[In-House] POTELLIGENT® Human Antibody-Producing Technology
		Atopic Dermatitis	JP US CA EU						
©ASKP1240 Bleselumab Injection	Anti-CD40 Fully Human Antibody	Recurrence of Focal Segmental Glomerulosclerosis (FSGS) in de novo kidney transplant recipients	US						[In-House] Human Antibody-Producing Technology Jointly Developed with Astellas



antibody protein small molecule

© New Molecular Entity

Updated since Dec. 31, 2019

Central Nervous System

As of Mar. 31, 2020

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KW-6002 Istradefylline Oral	Adenosine A2A Receptor Antagonist	Parkinson's Disease	EU						[In-House]
KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	HTLV-1 associated myelopathy (HAM)	JP						[In-House] POTELLIGENT®
©KW-6356 Oral	Adenosine A2A Receptor Antagonist	Parkinson's Disease	JP						[In-House]
©KHK6640 Injection	Anti-Amyloid Beta Peptide Antibody	Alzheimer's Disease	JP EU						[Immunas Pharma]

Other

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH)	CH						[In-House] Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
			TW						
			KW SA CN HK SG BH OM						
			Adult X-linked Hypophosphatemia (XLH)						
		FGF23-Related Hypophosphatemic Rickets and Osteomalacia	EU						
		Tumor Induced Osteomalacia (TIO)	KR						
AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia Who Have Had an Inadequate Response to Conventional Therapy	US						[Kirin-Amgen]
			JP KR US						
		Idiopathic (Immune) Thrombocytopenic Purpura	TW						
		Aplastic Anemia Who Were Previously Untreated with Immunosuppressive Therapy	CN						
KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	EU						[In-House]